Wosulin-N 40IU/ml Suspension for Injection

Product Overview

About Wosulin-N 40IU/ml Suspension for Injection

Wosulin-N 40IU/ml Suspension for Injection is a pharmaceutical preparation containing insulin isophane as its active ingredient. It is formulated as a clear, sterile suspension designed for intramuscular or subcutaneous injection. The product is intended for the management of diabetes mellitus in patients who require long‑acting insulin therapy. Each vial contains a concentration of 40 international units per milliliter, allowing for precise dosing according to individual therapeutic needs. The suspension is packaged in a single‑use vial with a pre‑filled syringe for ease of administration. The formulation is free from common excipients that may cause hypersensitivity reactions in susceptible individuals. Wosulin-N is manufactured under strict quality control standards to ensure sterility, potency, and stability throughout its shelf life. The product is supplied in a refrigerated environment and should be stored at 2°C to 8°C until use. Healthcare professionals should follow the manufacturer’s guidelines for reconstitution, storage, and administration to achieve optimal glycaemic control.

Key Benefits & Uses

• Provides a steady, long‑acting insulin release to maintain basal glucose levels.
• Reduces the frequency of injections compared to rapid‑acting insulin formulations.
• Helps achieve stable glycaemic control in patients with type 1 or type 2 diabetes.

Active Ingredient & Action

The active ingredient, insulin isophane, is a crystalline form of human insulin that is slowly absorbed after injection. It mimics the body’s natural basal insulin secretion, thereby lowering blood glucose levels over an extended period. The pharmacokinetic profile of insulin isophane allows for once‑daily dosing in many patients, improving adherence and reducing the risk of hypoglycaemic episodes associated with more rapid insulin preparations.

Important Notes

Wosulin-N 40IU/ml Suspension for Injection should be used only under the supervision of a qualified healthcare provider. Patients should be instructed on proper injection technique, rotation of injection sites, and storage conditions. The product must be kept refrigerated and protected from light. Before use, the vial should be inspected for particulate matter or discoloration; any suspicious vial must be discarded. Patients with a known allergy to insulin or any component of the formulation should avoid use. Regular monitoring of blood glucose levels is essential to adjust dosing and to detect potential hypoglycaemic events. For further information, consult the prescribing information or contact the manufacturer’s customer service line.